Phase 3 Colorectal Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able and willing to provide written consent before any study procedures begin
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by standard medical scoring tools (confirm with trial site)
- People whose kidneys, liver, and bone marrow are functioning well enough, based on blood and laboratory tests
- Women who could potentially become pregnant must have a negative pregnancy test on record before joining
- People aged 18 to 78 years old
- People diagnosed with colorectal cancer that has spread to the lining of the abdomen (peritoneum), with or without a small number of liver metastases (up to 3)
- People who also have lung metastases that surgeons consider removable may still be considered
- People who a specialist medical team (a HIPEC multidisciplinary board) has assessed as suitable for a combined surgery and heated chemotherapy procedure (CRS and HIPEC)
Who may not be able to join:
- People who have previously had a severe reaction or serious side effects from certain chemotherapy drugs (oxaliplatin, irinotecan, or 5-fluorouracil)
- People whose other health conditions mean they would not be able to safely tolerate the planned treatment
- People whose cancer has spread to areas other than the abdominal lining, liver, or lungs
- People who would require complex or extensive liver surgery as part of their treatment
- People who have previously undergone CRS or HIPEC treatment
- Women who are pregnant or currently breastfeeding
- People who currently have an active infection being treated with antibiotics
- People with active hepatitis B, active hepatitis C, or known HIV infection
- People who have received any other cancer treatment within 4 weeks before or up to 4 weeks after the study treatment
- People where surgeons were not able to remove all visible cancer during the procedure (confirm with trial site)
- People whose cancer originated from somewhere other than the colon or rectum
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Peter Cashin, MD, PhD, Uppsala University Hospital
Phone: +46 (0)18 6174304
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recurrence-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.